Combination effect of edible mushroom – sliver nanoparticles and antibiotics against selected multidrug biofilm pathogens

Le résumé fourni par la source

Objective This project was designed to determine the effect of edible mushroom-Ag-Nps in combination with conventional antibioticsagainst selected multidrug biofilm-forming pathogens.Methods Biofilm-producing bacteria were isolated and identified using routine cultural and biochemical tests from clinical specimen.In addition to that, standard bacterial strains were used. Silver nanoparticles were prepared using edible mushroom as bio-reductant. The biosynthesis of Ag–Nps was characterized by changing mushroom extract color from clear yellow to brown and UV/Visual spectrophotometer and electronic microscope. Then, the Ag–Nps were tested against bacterial strains and biofilm-producing bacteria using diffusion method as antibacterial agents in combination with antibiotics.Results Biosynthesized Ag–Nps characterized by visual spectroscopy, scanning electronic microscope (SEM) were ranged (5–50 nm) insize, and Fourier Transform Infrared Spectroscopy (FTIR) in peak 430 cm-1 refers to protein formation. Different volumes and concentrationof Ag-Nps (20, 30, and 50 μl) tested against selected multi drug biofilm-producing pathogens showed Ag–NPs at concentration 50 μl. Theywere more efficient in the inhibition of bacterial growth. On the other hand, assessment of the consolidated impact was examined utilizingcircle dissemination strategy against methicillin-resistants, such as Staphylococcus aureus (MRSA), Escherichia coli, Pseudomonas aeruginosaand Proteus mirabilis. Results recorded a synergetic effect of Ag–Nps in association with resistant antibiotics.Conclusions Compounds with greater potential as antimicrobial against pathogenic micro-organisms in combination with nanoparticles inhibited effectively to form biofilm than antibiotics alone. From this, we can conclude that Ag–NPs may be used in the remediation of infectious diseases. So Ag–NPs with antibiotics show maximum antibacterial activity. This may lead to develop new drugs for therapeutic needs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.